eupraxia Archives - Vista Partners LLC

The Esophagus Economy: How EP‑104GI Could Reshape EoE Treatment—and Eupraxia’s Valuation -( $EPRX $REGN $SNY )

by John F. Heerdink, Jr. 19 hours ago 61Views 0Likes

Eupraxia Pharmaceuticals, Inc. (NASDAQ: EPRX) is quietly setting up one of the more intriguing biotech inflection points on Wall Street as it marches toward Phase 2b data for EP‑104GI in eosinophilic esophagitis (EoE) this December, with investors increasingly framing the “bar” in…

Cash, Catalysts and Credentials: Why Agenus and Eupraxia Are Starting to Screen In -( $AGEN $EPRX $XBI )

by John F. Heerdink, Jr. July 13, 2026 208Views 0Likes

Agenus Inc. (NASDAQ: AGEN) and Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX, TSX: EPRX) just offered Wall Street a reminder that in biotech, capital and human capital still set the tempo—one via an oversubscribed private placement, the other via a board refresh that reads…

The Immune System Strikes Back: Why Biogen’s M&A Spree and Eupraxia’s Trial Progress Deserve a Place On Your Radar -( $APLS $BIIB $EPRX )

by John F. Heerdink, Jr. July 3, 2026 257Views 0Likes

Biogen Inc. (Nasdaq: BIIB) is quietly rewriting its own playbook, stitching together a next‑generation immunology franchise with a $1 billion bet on private upstart RayThera Inc. and a freshly closed $5.6 billion takeover of Apellis Pharmaceuticals Inc. (Nasdaq: APLS) that gives the…

Biologics, Blister Bulls, EOE and Yearly Shots: Why Sanofi and Eupraxia Belong on Every Immunology Watchlist -( $EPRX $REGN $SNY )

by John F. Heerdink, Jr. June 19, 2026 448Views 0Likes

Sanofi’s latest Dupixent win and Eupraxia Pharmaceuticals’ quiet grind in eosinophilic esophagitis (“EoE”) still tell a coherent, investor‑friendly story: the type 2 inflammation boom is alive, and there is room on the highway for both mega‑cap platforms and focused innovators. For investors,…

Eupraxia, Dupixent, and the Race to Redefine EoE Care -( $EPRX $REGN $SNY )

by John F. Heerdink, Jr. May 18, 2026 400Views 0Likes

Eupraxia’s (NASDAQ: EPRX) current analyst chorus post their most recent First Quarter 2026 Financial Results report is now singing from the same hymn book: this is a late-stage GI platform story with cash in the bank, near-term catalysts, and price targets that…

From Weekly Jabs to Yearly Scopes: Why Eupraxia’s EP‑104GI Might Have Sanofi Checking Its Calendar – ( $EPRX $SNY $XBI )

by John F. Heerdink, Jr. May 6, 2026 414Views 0Likes

Eupraxia’s (NASDAQ: EPRX) latest data drop puts eosinophilic esophagitis (EoE) firmly at center stage, with fresh endoscopic and long‑term clinical results suggesting EP‑104GI could emerge as a once‑yearly, procedure‑based alternative to chronic biologic regimens such as Sanofi’s (SNY) multi-billion dollar weekly-injectable drug…

From Molecules to Millions: How Eupraxia, Eli Lilly and Merck Navigate the FDA Maze -( $EPRX $LLY $MRK )

by John F. Heerdink, Jr. May 4, 2026 301Views 0Likes

The modern FDA approval maze is becoming less a straight corridor and more a high-speed roundabout—and investors riding with Eupraxia Pharmaceuticals (EPRX), Eli Lilly (LLY) and Merck (MRK) may find that’s exactly where outsized opportunity lives. From Wall Poster to Wall Street…

Eupraxia’s EP-104 Is Quietly Auditioning for a Starring Role In Eosinophilic Esophagitis -( $EPRX $SNY $TAK $IBB $XBI )

by John F. Heerdink, Jr. March 25, 2026 558Views 0Likes

Yes indeed, Eupraxia Pharmaceutical's (NASDAQ: EPRX) EP-104 is quietly auditioning for a starring role in eosinophilic esophagitis—and for once, the gastroenterologist, the allergist, and the payer might actually clap at the same time. A Chronic Disease Finally Meets a Long-Term Plan Eosinophilic…

Eupraxia Steps Into the Spotlight: AAAAI 2026 Puts EoE Back on the Growth Map -( $EPRX $SNY $REGN $IBB $XBI )

by John F. Heerdink, Jr. March 2, 2026 554Views 0Likes

In a conference season dominated by mega-cap immunology franchises, Eupraxia Pharmaceuticals (NASDAQ: EPRX) quietly walked into AAAAI 2026 and walked out looking a lot less “micro‑cap” and a lot more “mispriced asset.” For investors willing to do more than skim the abstracts,…

Eupraxia’s Latest Raise: A Diffusphere-Fueled War Chest Aims at GI Disease -( $EPRX $IBB $XBI $SNY)

by John F. Heerdink, Jr. February 21, 2026 369Views 0Likes

In a market that has grown wary of “story stocks,” Eupraxia Pharmaceuticals (NASDAQ: EPRX) just delivered something refreshingly old-fashioned: a fully closed, upsized equity offering that actually funds a clinical plan rather than a marketing slogan. The clinical‑stage biotech, which trades on…

Tag: eupraxia

The Esophagus Economy: How EP‑104GI Could Reshape EoE Treatment—and Eupraxia’s Valuation -( $EPRX $REGN $SNY )

Cash, Catalysts and Credentials: Why Agenus and Eupraxia Are Starting to Screen In -( $AGEN $EPRX $XBI )

The Immune System Strikes Back: Why Biogen’s M&A Spree and Eupraxia’s Trial Progress Deserve a Place On Your Radar -( $APLS $BIIB $EPRX )

Biologics, Blister Bulls, EOE and Yearly Shots: Why Sanofi and Eupraxia Belong on Every Immunology Watchlist -( $EPRX $REGN $SNY )

Eupraxia, Dupixent, and the Race to Redefine EoE Care -( $EPRX $REGN $SNY )

From Weekly Jabs to Yearly Scopes: Why Eupraxia’s EP‑104GI Might Have Sanofi Checking Its Calendar – ( $EPRX $SNY $XBI )

From Molecules to Millions: How Eupraxia, Eli Lilly and Merck Navigate the FDA Maze -( $EPRX $LLY $MRK )

Eupraxia’s EP-104 Is Quietly Auditioning for a Starring Role In Eosinophilic Esophagitis -( $EPRX $SNY $TAK $IBB $XBI )

Eupraxia Steps Into the Spotlight: AAAAI 2026 Puts EoE Back on the Growth Map -( $EPRX $SNY $REGN $IBB $XBI )

Eupraxia’s Latest Raise: A Diffusphere-Fueled War Chest Aims at GI Disease -( $EPRX $IBB $XBI $SNY)

Your Guide To Staying Informed In The Markets